Adial Pharmaceuticals (NASDAQ: ADIL) stock is up 90%. ADIL stock rose on a burst of trade yesterday and we think that this is likely to lead to some issuance of stock. Partly this is because we're simply cynics - to the point that we did wonder whether the stock price rise was caused by the desire to issue more stock. But no, we're not actually that cynical. However, it is true that ADIL needs to issue more stock, it has the capability to do so and a rising stock price is a great time to make such an issue. So, that's what we expect will happen.
At to what goes on inside Adial: “Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.” Someone in Phase III trials is doing real work, there's a proper company in there. This doesn't mean the trials will be successful, that's not how it works. But we are here looking at someone at least trying to develop a real treatment. One which, if it works, we'd expect to find a ready market.

Adial Pharmaceuticals stock price from NASDAQ
However, because we are cynics we thought we'd have a look for actual news that might be driving this ADIL stock price rise. There are three interesting filings at Edgar (the SEC's information service). One is that Adial is out of conformance with the NASDAQ listing rules ( Nasdaq stating that the Company was not in compliance with the Rule because the stockholders' equity of the Company of $1,439,848 as of March 31, 2023, as reported in the Company's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2023, was below the minimum requirement of $2,500,000.) so it needs another $million in capital.
The second is that quarterly losses of around the $3 million mark (nothing wrong with that at this stage of the testing process) meet cash balances of about $3 million (rough numbers). The third is that there's already a registration to enable the issuance of more stock.
So, we expect more stock to be issued to solve the two problems of capital requirement and the cash pile. A rising stock price is an excellent time to be issuing more stock - therefore we expect this to happen. We'd also expect the stock price rise to be blunted by the issuance of more stock. That is, we don't expect this rally to last all that long. Yes, it's entirely true there are approving noises from regulators. But we still expect that stock issue.



